Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cardiovascular Magnetic Resonance In The Oncology Patient

J. Jordan, R. M. Todd, S. Vasu, W. Hundley
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Patients with or receiving potentially cardiotoxic treatment for cancer are susceptible to developing decrements in left ventricular mass, diastolic function, or systolic function. They may also experience valvular heart disease, pericardial disease, or intracardiac masses. Cardiovascular magnetic resonance may be used to assess cardiac anatomy, structure, and function and to characterize myocardial tissue. This combination of features facilitates the diagnosis and management of disease processes in patients with or those who have survived cancer. This report outlines and describes prior research involving cardiovascular magnetic resonance for assessing cardiovascular disease in patients with or previously having received treatment for cancer.
This paper references
10.1002/cam4.200
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
E. Culakova (2014)
10.1136/hrt.73.1.61
Impairment of diastolic function during short-term anthracycline chemotherapy.
Y. Cottin (1995)
10.1200/JCO.2011.40.3584
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.
G. Armstrong (2012)
10.1016/0002-9343(87)90212-9
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
10.1016/S1040-8428(01)00227-X
Radiation-associated cardiovascular disease.
M. Adams (2003)
10.1056/NEJM199907293410515
Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging.
S. Kojima (1999)
10.1200/JCO.1984.2.2.112
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
M. Ewer (1984)
A Prospective Study of Breast Cancer Patients with Abnormal Strain Imaging
10.1161/CIR.0b013e3181d44a8f
ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
W. Hundley (2010)
10.1016/j.jacc.2010.11.013
Assessment of myocardial fibrosis with cardiovascular magnetic resonance.
N. Mewton (2011)
[Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
K. Oberholzer (2004)
10.1016/j.jcmg.2017.11.036
Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors.
S. Edérhy (2018)
10.1371/journal.pone.0057554
Weekly Doxorubicin Increases Coronary Arteriolar Wall and Adventitial Thickness
D. Eckman (2013)
10.1371/journal.pone.0074675
Creatine Kinase-Overexpression Improves Myocardial Energetics, Contractile Dysfunction and Survival in Murine Doxorubicin Cardiotoxicity
Ashish Gupta (2013)
10.1016/J.AMJCARD.2005.01.094
Relation of acute pericardial disease to malignancy.
M. Imazio (2005)
10.1001/jamaneurol.2015.2960
Blood-Brain Barrier Permeability and Gadolinium: Benefits and Potential Pitfalls in Research.
A. Montagne (2016)
10.1161/CIRCULATIONAHA.114.013777
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
D. Cardinale (2015)
10.1038/nm.2919
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang (2012)
Early myocardial strain changes during potentially car - diotoxic chemotherapy may occur as a result of reductions in left ventricular end - diastolic volume
JH Jordan (2017)
Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among longterm survivors of childhood cancer
K Ylänen (2013)
Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation
H Mahrholdt (2004)
10.1056/NEJMOA1609214
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
D. Johnson (2016)
10.7326/0003-4819-152-12-201006150-00026
Tako-tsubo (stress-induced) cardiomyopathy and cancer.
C. Burgdorf (2010)
10.1148/RG.23SI035504
CT and MR imaging of pericardial disease.
Z. Wang (2003)
Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume. Circulation 2017;135:2575–7
JH Jordan (2017)
10.5603/nmr-18727
Equilibrium radionuclide ventriculography in the assessment of cardiotoxicity of chemotherapy and chemoradiotherapy in patients with breast cancer.
G. Lapińska (2012)
10.1016/j.jcmg.2014.05.009
Value of CMR for the differential diagnosis of cardiac masses.
Pablo Pazos-López (2014)
10.1016/J.JACC.2005.09.036
Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA).
L. Wang (2006)
diac energetics , oxygenation , and perfusion during increased workload in patients with type 2 diabetes mellitus
E Levelt (2016)
Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of
L Wang
Available at: https:// clinicaltrials.gov/ct2/show/NCT02080390. Accessed
10.1097/COC.0b013e31829e19be
Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy
M. Lunning (2015)
10.1186/s12968-017-0356-4
Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study
A. Barthur (2017)
10.1161/CIRCULATIONAHA.112.000438
Quantification of Cardiomyocyte Hypertrophy by Cardiac Magnetic Resonance: Implications for Early Cardiac Remodeling
O. Coelho-Filho (2013)
10.1097/QCO.0000000000000202
Can mortality of cancer patients with fever and neutropenia be improved?
K. Thursky (2015)
10.1016/j.jacc.2015.04.059
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.
A. Barac (2015)
10.1186/1532-429X-11-14
Cardiovascular magnetic resonance in pericardial diseases
J. Bogaert (2009)
Cardiac amyloidosis: MR imaging findings
GA Krombach (2007)
10.1161/CIRCIMAGING.109.918540
Early Detection of Doxorubicin Cardiotoxicity Using Gadolinium Enhanced Cardiovascular Magnetic Resonance Imaging
James C. Lightfoot (2010)
10.1016/j.jacc.2018.02.037
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Syed S Mahmood (2018)
Effect of aging on myocardial perfusion reserve.
N. Uren (1995)
10.1053/j.seminoncol.2013.01.009
Infiltrative cardiomyopathy and pericardial disease.
S. Yusuf (2013)
10.1016/j.jacc.2011.01.024
Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function.
Shu-Guang Zhu (2011)
10.1016/S0895-7061(02)03029-7
Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications.
A. Benetos (2002)
10.1016/J.AHJ.2005.04.029
Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance.
S. Raman (2006)
10.1161/CIRCULATIONAHA.117.027930
Early Myocardial Strain Changes During Potentially Cardiotoxic Chemotherapy May Occur as a Result of Reductions in Left Ventricular End-Diastolic Volume: The Need to Interpret Left Ventricular Strain With Volumes.
J. Jordan (2017)
10.1056/NEJMRA1100265
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
J. Moslehi (2016)
10.1042/CS20160479
Pathophysiology of exercise intolerance in breast cancer survivors with preserved left ventricular ejection fraction.
M. Haykowsky (2016)
10.1186/s40959-016-0011-5
Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures
A. Yu (2016)
10.1177/2042098614529603
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
A. Onitilo (2014)
10.1016/j.jcmg.2011.08.011
Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy: a case series with histopathological correlation.
Andrew O. Zurick (2011)
10.1002/(SICI)1522-2594(199912)42:6<1048::AID-MRM9>3.0.CO;2-M
Cardiac motion tracking using CINE harmonic phase (HARP) magnetic resonance imaging
N. Osman (1999)
10.1016/0022-2836(92)90863-F
Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.
B. Sørensen (1992)
10.1016/S0960-9776(02)00273-4
Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
M. Bilous (2003)
10.1016/j.jacc.2009.02.007
Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.
M. Friedrich (2009)
Evaluation of Myocardial Changes During Breast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI (EMBRACE-MRI)
10.1016/j.jchf.2012.09.001
The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
P. S. Hall (2013)
10.1093/ehjci/jeu192
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
J. Plana (2014)
10.1002/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8
Primary systemic amyloidosis with delayed progression to multiple myeloma
S. Rajkumar (1998)
10.1177/1358863X10388346
Peripheral arterial ischemic events in cancer patients
Saurabh Sanon (2011)
10.1161/CIRCIMAGING.113.000798
Occult Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy
Olga H. Toro-Salazar (2013)
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
10.1186/1532-429X-15-92
Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
J. Moon (2013)
10.3109/10428199709059685
Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
K. Desikan (1997)
10.1161/CIR.0000000000000031
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
R. Nishimura (2014)
10.1067/MHJ.2001.115436
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study.
R. Wassmuth (2001)
Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role Jordan
AF Yu (2015)
10.1136/bmj.b4606
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
D. Mulrooney (2009)
10.1161/CIRCIMAGING.114.002217
Longitudinal Assessment of Concurrent Changes in Left Ventricular Ejection Fraction and Left Ventricular Myocardial Tissue Characteristics After Administration of Cardiotoxic Chemotherapies Using T1-Weighted and T2-Weighted Cardiovascular Magnetic Resonance
J. Jordan (2014)
10.1016/j.pcad.2010.06.003
Evaluation and management of pericardial effusion in patients with neoplastic disease.
B. Maisch (2010)
10.1111/imj.12645
Early and late changes in markers of aortic stiffness with breast cancer therapy
S. Grover (2015)
10.1111/j.1743-7563.2011.01462.x
Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer
C. Lawley (2012)
10.1161/CIRCHEARTFAILURE.117.004560
Left Ventricular Mass Change After Anthracycline Chemotherapy
J. Jordan (2018)
10.1186/s12968-017-0390-2
Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer
Angel T Chan (2017)
10.1007/s10554-016-1034-6
Magnetic resonance evaluation of cardiac thrombi and masses by T1 and T2 mapping: an observational study
T. Caspar (2016)
10.1016/j.jcmg.2012.11.017
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Brandon C. Drafts (2013)
10.1093/ejechocard/jer187
Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.
P. Stoodley (2011)
10.1053/EUHJ.2000.2011
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?
N. Bellenger (2000)
10.1053/EUHJ.2001.3038
Assessment of myocardial viability by cardiovascular magnetic resonance imaging.
H. Mahrholdt (2002)
10.1186/1532-429X-15-35
Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing
J. Schulz-Menger (2013)
10.1016/j.amjcard.2012.11.022
Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
T. Neilan (2013)
10.1136/heartjnl-2011-301481
Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI
Christopher Neil (2012)
10.1139/Y94-022
Early incidence of adriamycin treatment on cardiac parameters in the rat.
Y. Cottin (1994)
10.1186/s12968-017-0373-3
Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy
M. Jolly (2017)
10.1161/CIRCIMAGING.112.973321
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya (2012)
10.1161/01.CIR.0000118493.13323.81
Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology
H. Mahrholdt (2004)
[Update on myocarditis].
M. Moonen (2018)
10.1016/j.jacc.2009.11.011
ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
W. Hundley (2010)
10.1016/j.ijcard.2009.03.067
Cardiac MRI studies of transient left ventricular apical ballooning syndrome (takotsubo cardiomyopathy): a systematic review.
G. Leurent (2009)
10.1016/j.hrtlng.2010.06.005
Long-term prognosis of transient left ventricular ballooning syndrome and cancer.
C. Burgdorf (2011)
10.1056/NEJM197902083000603
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
10.1016/j.jcmg.2014.06.007
Noninvasive imaging of cardiovascular injury related to the treatment of cancer.
Suwat Kongbundansuk (2014)
10.1161/CIRCIMAGING.115.004325
Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors
J. Jordan (2016)
10.1002/pbc.26924
Exercise program for children and adolescents with leukemia and lymphoma during treatment: A comprehensive review
Giulia Zucchetti (2018)
10.1021/tx9003424
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
P. Menna (2010)
Slowly resolving global myocardial inflammation/oedema in tako-tsubo cardiomyopathy: evidence from T2weighted cardiac MRI. Heart 2012;98:1278–84
C Neil (2012)
10.1200/JCO.2016.70.0229
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
K. Wang (2017)
10.1016/j.jacc.2014.02.536
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
R. Nishimura (2014)
10.1186/s12968-015-0111-7
Normal values for cardiovascular magnetic resonance in adults and children
N. Kawel-Boehm (2015)
10.1007/s10549-018-4663-8
Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial
S. Mijwel (2018)
10.1200/JCO.2009.23.8527
Aortic stiffness increases upon receipt of anthracycline chemotherapy.
Narumol Chaosuwannakit (2010)
10.1053/EUHJ.2001.2822
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.
L. Anderson (2001)
10.1016/j.jacc.2013.01.019
Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer.
Kaisa Ylänen (2013)
10.1161/CIR.0B013E3181D44A8F
ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Accf Task Force Members (2010)
10.1200/JCO.2009.26.7294
Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
J. Walker (2010)
10.1161/JAHA.117.006604
Lower Mitochondrial Energy Production of the Thigh Muscles in Patients With Low‐Normal Ankle‐Brachial Index
M. AlGhatrif (2017)
10.1016/S0140-6736(11)61335-4
Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial
J. Greenwood (2012)
10.1161/CIRCULATIONAHA.117.027740
Association of Feature-Tracking Cardiac Magnetic Resonance Imaging Left Ventricular Global Longitudinal Strain With All-Cause Mortality in Patients With Reduced Left Ventricular Ejection Fraction.
S. Romano (2017)
10.1148/radiol.14140433
Comparison of the Diagnostic Performance of Four Quantitative Myocardial Perfusion Estimation Methods Used in Cardiac MR Imaging: CE-MARC Substudy.
J. Biglands (2015)
10.1007/s00109-008-0434-z
ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity
Junfeng An (2008)
10.1016/S0894-7317(99)70031-3
Myxoma of the mitral valve: diagnosis by 2-dimensional and 3-dimensional echocardiography.
M. Handke (1999)
10.1161/CIRCHEARTFAILURE.117.004129
Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure
K. Weiss (2017)
10.2165/00002018-200831060-00002
Cardiotoxicity Profile of Trastuzumab
S. Ewer (2008)
10.1016/j.ijcard.2009.09.564
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
M. Feola (2011)
10.1016/0002-8703(87)90660-0
Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties.
R. Thompson (1987)
10.1016/0002-9149(83)90084-X
Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients.
W. Roberts (1983)
10.1016/j.jacc.2010.11.063
The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
N. Fallah-Rad (2011)
KEY WORDS cardio-oncology, cardiovascular magnetic resonance, tissue characterization APPENDIX For supplemental videos, please see the online version of this paper
10.1148/radiol.15150025
Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
R. McDonald (2015)
10.1038/sj.bjc.6604909
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
A. Jones (2009)
10.1097/RLI.0000000000000252
Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function
N. Murata (2016)
10.1186/1532-429X-15-66
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance
S. Vasu (2013)
10.1186/1532-429X-10-5
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
N. Fallah-Rad (2008)
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance
N Bellenger (2000)
10.1124/mol.63.2.368
Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis.
Y. Kim (2003)
Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio.
A. Childs (2002)
10.1002/jmri.20917
Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects
G. Krombach (2007)
10.1093/eurheartj/ehv442
Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus
E. Levelt (2016)
10.1164/rccm.201304-0744LE
Nonischemic myocardial changes detected by cardiac magnetic resonance in critical care patients with sepsis.
Yasmin Siddiqui (2013)
10.1007/s11886-017-0835-0
Cardiovascular Toxicities Associated with Cancer Immunotherapies
D. Wang (2017)
10.3399/bjgp18X695861
Cancer and the heart.
R. Dobson (2018)
10.1007/s10549-008-0260-6
Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
D. Wadhwa (2008)
10.1006/JMRE.1998.1676
DENSE: displacement encoding with stimulated echoes in cardiac functional MRI.
A. Aletras (1999)
10.1161/CIRCIMAGING.109.918540
Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolinium-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model
James C. Lightfoot (2010)
10.1186/1532-429X-15-48
Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling
E. Tham (2013)
10.2337/dc10-1446
Cerebral Perfusion and Aortic Stiffness Are Independent Predictors of White Matter Brain Atrophy in Type 1 Diabetic Patients Assessed With Magnetic Resonance Imaging
S. V. van Elderen (2011)
1 1 , N O . 8 , 2 0 1 8 and mechanisms of aerobic training
G VOLJACCCARDIOVASCULARIMAGIN (2015)
10.1146/annurev-clinpsy-050817-084903
Cognitive Effects of Cancer and Cancer Treatments.
T. Ahles (2018)
10.1097/MNM.0B013E328025AE04
Trastuzumab-induced cardiac dysfunction.
G. Panjrath (2007)
10.2459/JCM.0b013e3283638011
Inside myocardial dysfunction in septic shock: mechanism of troponin release highlighted by cardiac magnetic resonance.
M. De Lazzari (2017)
10.1161/HC3401.095198
Advances in the understanding of myocarditis.
P. Liu (2001)
of Breast Cancer Patients with Abnormal Strain Imaging
A Prospective Stud (2018)
10.1016/j.ejheart.2008.07.008
Long‐term prognosis of the transient left ventricular dysfunction syndrome (Tako‐Tsubo cardiomyopathy): Focus on malignancies
C. Burgdorf (2008)
10.1016/j.jacc.2014.01.073
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
P. Thavendiranathan (2014)
Anthracycline-associated T1 mapping characteris
J H Jordan
10.1148/rg.336125005
Cardiac complications of oncologic therapy.
C. Walker (2013)
10.1093/eurheartj/ehr104
Cardiovascular magnetic resonance imaging for diagnosis and clinical management of suspected cardiac masses and tumours.
Sandra Fussen (2011)
10.1007/s10554-013-0357-9
Detection of intracardiac masses in patients with coronary artery disease using cardiac magnetic resonance imaging: a comparison with transthoracic echocardiography
W. Staab (2013)
10.1016/j.ahj.2009.05.031
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
J. Hare (2009)
10.1016/j.jacc.2012.09.035
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
P. Thavendiranathan (2013)
10.1016/j.amjcard.2017.02.008
Frequency of Left Ventricular End-Diastolic Volume-Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment.
Giselle C. Meléndez (2017)
10.1016/J.BBAGEN.2005.10.012
The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction.
M. B. Wolf (2006)
10.1200/JCO.2005.03.5956
Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study.
A. Chow (2006)
10.1161/CIRCULATIONAHA.107.697763
Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis
D. Feng (2007)
10.1152/ajpheart.00517.2014
ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.
Frances Belmonte (2015)
10.2217/fca.15.29
Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.
A. Yu (2015)
10.1016/j.jacc.2015.07.025
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
Weijuan Li (2015)
MR evaluation of the pericardium and cardiac malignancies.
C. White (1996)
Progressive 3month increase in left ventricular myocardial extracellular volume fraction after receipt of anthracycline based chemotherapy
GC Meléndez (2016)
diotoxicity after anthracycline chemotherapy in breast carcinoma : effects on left ventricular ejection fraction , troponin I and brain natriuretic peptide
M Feola (2011)
bone tissue: preliminary results from 9 patients with normal renal function
N Murata (2016)
10.1016/j.amjcard.2012.07.040
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
T. Neilan (2012)
10.1055/S-2004-813416
Anthrazyklin-induzierte Kardiotoxizität: MRT des Herzens bei Kindern und Jugendlichen mit malignen Erkrankungen
K. Oberholzer (2004)



This paper is referenced by
10.1002/jmri.26895
MRI in cardio‐oncology: A review of cardiac complications in oncologic care
Daniel Jeong (2019)
10.32635/2176-9745.rbc.2019v65n3.388
Opções Contemporâneas de Rastreio da Cardiotoxicidade Relacionada a Tratamentos Oncológicos
B. H. paula (2019)
10.1002/ehf2.12450
Health care utilization and mortality associated with heart failure‐related admissions among cancer patients
A. Guha (2019)
10.1186/s12885-020-07104-9
Cardio-toxicity among patients with sarcoma: a cardio-oncology registry
S. Shamai (2020)
10.1007/s10554-020-02061-7
Left ventricular mechanics in patients with hematological malignancies before initiation of chemo- and radiotherapy
Milan Pavlovic (2020)
10.3390/jcm10010154
The Role of Speckle Strain Echocardiography in the Diagnosis of Early Subclinical Cardiac Injury in Cancer Patients—Is There More Than Just Left Ventricle Global Longitudinal Strain?
Michal Laufer-Perl (2021)
10.1016/j.ccl.2019.07.007
MRI of Cardiotoxicity.
J. Jordan (2019)
10.1002/ejhf.1957
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)
J. Celutkiene (2020)
10.1016/j.jaccao.2020.04.011
Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review
I. Harries (2020)
10.2967/jnumed.118.220137
Precision Cardio-Oncology
Alexandra D Dreyfuss (2019)
10.26182/5de8d20c7f73d
The role of exercise in the diagnosis and treatment of long-term and late effects of childhood cancer
Treya M Long (2019)
10.1371/journal.pone.0223125
Does self-reported pregnancy loss identify women at risk of an adverse cardiovascular phenotype in later life? Insights from UK Biobank
E. Elmahi (2019)
10.1007/s10741-019-09813-1
Takotsubo syndrome: an overview of pathophysiology, diagnosis and treatment with emphasis on cancer patients
Isabela Bispo Santos da Silva da Costa (2019)
10.1007/s12350-018-01564-0
Looking for trouble: Reduced myocardial flow reserve following anthracyclines
M. C. Ziadi (2019)
Differences Between the Pathophysiology of Myocardial Infarction Related Cardiomyopathy and Anthracycline Related Cardiomyopathy
Tjerk Tjerk Scheepstra (2019)
10.1016/j.jacc.2020.08.079
Cardio-Oncology Education and Training: JACC Council Perspectives.
Jose Alvarez-Cardona (2020)
10.1161/JAHA.119.015400
Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2‐Year Postchemotherapy Measures of Left Ventricular Ejection Fraction
Cynthia K. Suerken (2020)
10.15420/cfr.2018.25.1
Subclinical Left Ventricular Dysfunction During Chemotherapy
Martin Nicol (2019)
10.1093/jnci/djaa177
Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils
Lauren A Baldassarre (2020)
10.1016/j.jcmg.2020.03.003
Cardiovascular Imaging Through the Prism of Modern Metrics.
A. Choi (2020)
10.1186/s40959-019-0047-4
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Treya M Long (2019)
10.1093/cvr/cvaa181
Remote Ischemic Preconditioning Ameliorates Anthracycline-induced Cardiotoxicity and Preserves Mitochondrial Integrity.
Carlos Galán‐Arriola (2020)
10.1016/s1936-878x(20)30301-6
Full Issue PDF
Leslee J. Shaw (2020)
10.1016/j.lpmfor.2020.05.017
Cancer du sein et cardiotoxicité des traitements : prévenir, dépister et structurer le suivi cardio-gynécologique
Martin Nicol (2020)
10.1016/j.jacc.2019.04.037
Reply: CMR and Tissue Characterization: Don't Forget the Strain!
Carlos Galán‐Arriola (2019)
10.1007/s12265-020-09981-8
The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges
Carolyn J. Park (2020)
10.1101/2020.03.20.000729
Remote Ischemic Preconditioning Ameliorates Anthracycline-induced Cardiotoxicity and Preserves Mitochondrial Integrity
Carlos Galán‐Arriola (2020)
10.1016/j.jcmg.2019.12.019
Serial Mapping for Evaluating Cardiac Therapies: Promising, But Not Perfect.
J. Sanz (2020)
10.1016/j.jaccao.2020.02.012
Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
J. Liu (2020)
10.1042/CS20200302
Cardiovascular toxicity of PI3Kα inhibitors.
Chandu Sadasivan (2020)
10.5935/2318-8219.20200002
Cardiotoxicity in cancer treatment: new frontiers in the multimodality diagnostic approach
J. B. D. A. Filho (2020)
10.3389/fonc.2020.506739
A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy
C. Bergom (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar